Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
World J Gastroenterol ; 23(28): 5086-5096, 2017 Jul 28.
Artigo em Inglês | MEDLINE | ID: mdl-28811705

RESUMO

Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. However, colon cancer incidence and mortality is declining over the past decade owing to adoption of effective screening programs. Nevertheless, in some parts of the world, CRC incidence and mortality remain on the rise, likely due to factors including "westernized" diet, lifestyle, and lack of health-care infrastructure and resources. Participation and adherence to different national screening programs remain obstacles limiting the achievement of screening goals. Different modalities are available ranging from stool based tests to radiology and endoscopy with varying sensitivity and specificity. However, the availability of these tests is limited to areas with high economic resources. Recently, FDA approved a blood-based test (Epi procolon®) for CRC screening. This blood based test may serve to increase the participation and adherence rates. Hence, leading to increase in colon cancer detection and prevention. This article will discuss various CRC screening tests with a particular focus on the data regarding the new approved blood test. Finally, we will propose an algorithm for a simple cost-effective CRC screening program.


Assuntos
Neoplasias Colorretais/diagnóstico , Detecção Precoce de Câncer/métodos , Fidelidade a Diretrizes , Programas de Rastreamento/métodos , Sangue Oculto , Colonoscopia/economia , Neoplasias Colorretais/economia , Neoplasias Colorretais/epidemiologia , Neoplasias Colorretais/prevenção & controle , Análise Custo-Benefício , Detecção Precoce de Câncer/economia , Detecção Precoce de Câncer/normas , Custos de Cuidados de Saúde , Humanos , Incidência , Programas de Rastreamento/economia , Programas de Rastreamento/normas , Medição de Risco
2.
Dig Dis Sci ; 57(10): 2633-41, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22427129

RESUMO

BACKGROUND: Stress ulcer prophylaxis (SUP) is commonly used in hospitals. Although its indications are better delineated for intensive care unit (ICU) patients, its use in non-ICU settings is somewhat arbitrary and based on judgment. OBJECTIVE: We attempted to assess the extent of SUP overuse in our hospital. We also carefully collected and analyzed several variables to detect associations governing this flawed behavior and its financial burden on the hospital's budget. MATERIALS AND METHODS: We retrospectively analyzed charts of patients admitted to the medical floor of a tertiary referral university hospital over a 1 year period. All adult patients admitted to the medical ward who received at least one dose of SUP were included and reviewed for a multitude of variables in addition to the appropriateness of acid suppression therapy (AST). RESULTS: We included 320 charts and found that 92% of patients admitted during that period were not eligible for SUP. The total inappropriateness of SUP was noted to be 58% (p = 0.015). Increasing age and male gender were found to be significant variables in AST misuse (p = 0.045 and p = 0.010), much like duration of hospital stay (p = 0.008). Comorbidities was also found to be a defining variable for AST overuse (odds ratio [OR] = 3.27). Patients with two or more minor risk factors were also subjected more to SUP inappropriately (OR = 3.53), in addition to patients of certain specialties (Neurology, Infectious Diseases, etc.). Our calculated financial burden was more than $23,000 per year for the medical floor. CONCLUSION: This retrospective study confirmed the growing suspicion that SUP misuse is evident on the medical floors. We also delineated several factors and variables associated with and affecting SUP overuse.


Assuntos
Antiulcerosos/uso terapêutico , Prescrição Inadequada , Úlcera Péptica/prevenção & controle , Estresse Fisiológico/fisiologia , Adulto , Idoso , Antiulcerosos/administração & dosagem , Antiulcerosos/economia , Custos e Análise de Custo , Uso de Medicamentos/economia , Feminino , Unidades Hospitalares , Humanos , Prescrição Inadequada/economia , Pacientes Internados , Masculino , Pessoa de Meia-Idade , Razão de Chances , Guias de Prática Clínica como Assunto , Estudos Retrospectivos , Fatores de Risco
3.
Int Med Case Rep J ; 3: 67-9, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-23754892

RESUMO

Epiploic appendagitis is a rare and uncommon diagnosis that is frequently unknown to clinicians. Inflammation is usually acute and causes abrupt symptoms, but once the diagnosis is accurately made, most patients respond to pain control and conservative management. We report the case of a young woman presenting with acute primary epiploic appendagitis of the right colon. The inflammatory mass was unusually large and occurred a few months after surgery for gastric bypass. This case will give us the opportunity to discuss the clinical presentation of this disease, as well as the potential associations and risk factors and the means for adequate diagnosis and treatment.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA